Literature DB >> 16379610

A conservative domain shared by HIV gp120 and EIAV gp90: implications for HIV vaccine design.

Huiguang Li1, Xiaoyan Zhang, Xiujuan Fan, Tao Shen, Xiao Tong, Rongxian Shen, Yiming Shao.   

Abstract

Both HIV and EIAV belong to the retroviridae family and lentivirus genus. Two variable regions (V3 and V4) of equine infectious anemia virus (EIAV) gp90 and two variable regions (V1 and V2) of HIV gp120 possibly adopt the same topology. We have studied the N-glycosylation properties and B cell linear epitope distribution profile of these two regions. Our results indicated that V3 and V4 of EIAV gp90 are very similar to V1 and V2 of HIV gp120. The differences between EIAV virulent and vaccine strains are mainly located at these two regions. Vaccine strains lose two N-glycosylation sites at these two regions. Because of the conservative domain shared by EIAV gp90 and HIV gp120, V1 and V2 of HIV gp120 and their glycosylation properties should be the regions preferably considered for HIV vaccine design.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16379610     DOI: 10.1089/aid.2005.21.1057

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  5 in total

1.  Selection of a rare neutralization-resistant variant following passive transfer of convalescent immune plasma in equine infectious anemia virus-challenged SCID horses.

Authors:  Sandra D Taylor; Steven R Leib; Susan Carpenter; Robert H Mealey
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

2.  Unique evolution characteristics of the envelope protein of EIAV(LN₄₀), a virulent strain of equine infectious anemia virus.

Authors:  Xuefeng Wang; Shuai Wang; Yuezhi Lin; Chenggang Jiang; Jian Ma; Liping Zhao; Xiaoling Lv; Fenglong Wang; Rongxian Shen; Jianhua Zhou
Journal:  Virus Genes       Date:  2011-01-08       Impact factor: 2.332

3.  Broader HIV-1 neutralizing antibody responses induced by envelope glycoprotein mutants based on the EIAV attenuated vaccine.

Authors:  Lianxing Liu; Yanmin Wan; Lan Wu; Jianping Sun; Huiguang Li; Haishan Li; Liying Ma; Yiming Shao
Journal:  Retrovirology       Date:  2010-09-01       Impact factor: 4.602

4.  Structural and biochemical insights into the V/I505T mutation found in the EIAV gp45 vaccine strain.

Authors:  Jiansen Du; Xuefeng Wang; Jing Ma; Jianxin Wang; Yuyin Qin; Chunhui Zhu; Fang Liu; Yiming Shao; Jianhua Zhou; Wentao Qiao; Xinqi Liu
Journal:  Retrovirology       Date:  2014-03-21       Impact factor: 4.602

5.  Genetic Evolution during the development of an attenuated EIAV vaccine.

Authors:  Xue-Feng Wang; Yue-Zhi Lin; Qiang Li; Qiang Liu; Wei-Wei Zhao; Cheng Du; Jie Chen; Xiaojun Wang; Jian-Hua Zhou
Journal:  Retrovirology       Date:  2016-02-03       Impact factor: 4.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.